CD8A and neoplasm: Poncette et al. (11) identified an HLA-DRA/DRB1*0401–restricted NY-ESO-1–specific CD4 TCR that caused tumor regression in combination with NY-ESO-1–redirected CD8+ T cells in a mouse model of adoptive T cell therapy.